JUN ZHI Biomedical Co., Ltd
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
CANCER SCREENING PROGRAM FOR DIGESTIVE SYSTEM
Founded Year
2018
Unified Business No.
69764282
Status
Active
Number of Employees
0
Total Paid-in
Capital
117,450,000 (NT$)
Location of Company
Taiwan
, Tainan City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
JUN ZHI Biomedical Co., Ltd. is a biotechnology team from Taiwan, and we have established research and development centers and Operations Center in National Biotechnology Research Park and Tainan Science Park respectively. The technologies authorized by many top research and development units, including Academia Sinica, National Tsing Hua University, National Yang-Ming University and Kaohsiung Medical University, etc. After many years of research and development, we developed the cancer screening service targeted on cancer of digestive system.
The technology of SAA MS screening and interpretation of MS spectra come from Academia Sinica. NTHU is responsible for the development of Magnetic Nanoparticles and antibody for extraction and purification of SAA. NYMU and Metal Industries Research & Development Centre help develop the bio-algorithms, making it more accurate. Last but not least, KMU work on clinical trials and the integration of clinical information to ensurethat SAA nano MS screening service has high accuracy and also help practically in the medical field.
The technology of SAA MS screening and interpretation of MS spectra come from Academia Sinica. NTHU is responsible for the development of Magnetic Nanoparticles and antibody for extraction and purification of SAA. NYMU and Metal Industries Research & Development Centre help develop the bio-algorithms, making it more accurate. Last but not least, KMU work on clinical trials and the integration of clinical information to ensurethat SAA nano MS screening service has high accuracy and also help practically in the medical field.
